FDA Brief

Warning letters Drugs

FDA warning letter to

Pacific Center of Health/Pacific Center of Health & Acupuncture

High riskIssued Jun 22, 2021Posted Jun 23, 2021Center for Drug Evaluation and Research

FDA warned Pacific Center of Health that its website sold herbal products and colloidal silver claimed to prevent or treat COVID-19 without approval.

What happened

FDA reviewed the company's website, www.pacificcenterofhealth.com, on June 2, 2021, and found products offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. The claims appeared on several product webpages and on labeling that shipped with the products. No facility inspection was reported.

What FDA found

  1. The products are new drugs sold without FDA approval because they are claimed to prevent or treat COVID-19.

    Section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a)
  2. The products are misbranded because their labeling makes misleading claims that they are safe and effective for COVID-19.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Putting these products into interstate commerce is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. Website pages and shipped labeling said the herbal formulas were "specifically formulated for combating COVID-19."

What FDA wants

FDA asked the company to immediately stop selling the unapproved COVID-19 products and, within 48 hours, email a description of each step taken and how it will prevent repeat violations, or explain why it cannot act that fast.

Who should pay attention

  • herbal and supplement brands making antiviral or immune claims
  • acupuncturists and clinics selling their own labeled remedies
  • online retailers and marketplaces listing COVID-19-related health products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk